International Association for the Study of Lung Cancer shared on LinkedIn:
“While the NRG/Alliance LU005 trial did not yield a survival benefit, Dr. Adam Schoenfeld says the study strengthens the case that sequencing matters with regard to immunotherapy timing.
You can also read “Targeted Therapy Resistance in NSCLC: Critical Next Steps”
